News | December 07, 2022
Concord Biotech gets SEBI nod for IPO
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio
Natco Chlorantraniliprole (CTPR) Process does not infringe FMC's Indian Patent 298645.
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Application includes data from key phase III trials, including the pivotal MOMENTUM trial, which met all primary and key secondary efficacy endpoints
Subscribe To Our Newsletter & Stay Updated
